E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
From 1 January 2027, Lilly’s US and international businesses will be combined under a new organisation, Lilly Global Markets, led by Ilya Yuffa.
imphoenix82
Eli Lilly’s oncology pipeline will feature at ESMO Congress 2026, with data presentations on investigational sofetabart mipitecan and olomorasib, alongside updated findings for Retevmo (selpercatinib) and Verzenio (abemaciclib).
imphoenix82
The FDA approval is based on Phase 3 data, with 42% of adolescent patients with severe alopecia areata receiving Olumiant 4 mg achieving at least 80% scalp hair coverage at Week 36, compared with 5% on placebo.
imphoenix82
AtaiBeckley has become a wholly owned subsidiary of Eli Lilly and Company.
imphoenix82
Lilly aims to advance treatments for serious autoimmune and allergic diseases with the Merida acquisition. The transaction is expected to close in the fourth quarter of 2026.
imphoenix82
Lilly is calling on regulators, customs agencies, law enforcement authorities, online platforms, and payment companies to shut down the illegal retatrutide black market.
imphoenix82
Lilly is currently evaluating olomorasib in the Phase 1/2 LOXO-RAS-20001 trial involving patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) and other advanced solid tumours.
imphoenix82
Novo Nordisk alleges Lilly’s advertisements for Zepbound and Mounjaro mislead consumers by comparing the drugs with lower-dose versions of Wegovy and Ozempic.
imphoenix82
As part of Eli Lilly’s new national campaign, O’Neal is sharing his personal experience with moderate-to-severe obstructive sleep apnea, including his diagnosis and treatment journey with Zepbound (tirzepatide).
imphoenix82
In addition to weight loss, women taking Foundayo also experienced notable reductions in waist circumference, suggesting reduced abdominal fat and cardiometabolic risk, according to Eli Lilly.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
